Pular para o conteúdo principal
Ranking Invest

MREO - Mereo BioPharma Group plc

Segmento: HealthcareMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Análise Ranking Invest

Valor de Mercado
$ 47.43 Mi
IVR
-2.36Índice proprietário de comparação relativa: -2,36.
IVR2
-3.03Leitura proprietária complementar: -303%.
MLL
-3.03Leitura proprietária complementar: -303%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 28.65 Mi

Dívida Líquida

-$ 30.12 Mi

L4T

-$ 28.10 Mi

Indicadores Básicos

ROE

-98.07%

Índices de Previsibilidade

Receita Líquida

G1.10

Lucro

C0.33

Margem

E1.29

Índices de Tendência

Receita Líquida

E-6.51

Lucro

C2.80

Margem

C4.25

Índices de Endividamento

DIV/PAT

-1.05

DIV/L4T

1.07

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.